WillItSurvive
Pharma and healthcare groups · South Korea

Chong Kun Dang

ckdpharm.com ↗

South Korean pharma maker selling generics, licensed drugs, and now Wegovy in Korea.

Defensible for now
Assessed 26 July 2026 · Evidence as of 26 July 2026
Real protection, with named pressure against it.
On the recordSince 26 July 2026 · Checkable from H2 2027 · Every call on the record Checkpoint: Novartis-led CKD-510 Phase 2 atrial fibrillation results
The call

CKD stays a top-five Korean pharma name, but its growth now leans on someone else's weight-loss drug while its own legacy products keep losing ground.

Chong Kun Dang makes and sells medicines in South Korea. It has stayed in business for 85 years because it knows how to get drugs approved by regulators, manufacture them reliably, and distribute them to pharmacies and hospitals, which competitors find hard to replicate quickly. But its own drugs are losing market share as patents expire and it is not inventing many new blockbuster medicines, so without the money it makes distributing Novo's Wegovy weight-loss drug, the company is actually shrinking. The key thing to watch is whether its older drugs stabilize in the next few quarters or keep falling faster. If they keep falling, Chong Kun Dang shifts from a steady, aging business to a genuinely declining one.

Why
01
AI pressure: None apparent. AI drug discovery tools could speed rivals' pipelines eventually, but nothing in this business today runs on AI or gets displaced by it. Could AI do the core job? Unlikely.
02
Bigger players: Novo Nordisk and Eli Lilly (GLP-1 makers). Wegovy sales now prop up growth while old drugs like Gliatilin and Prolia shrink; CKD depends on a Novo deal it doesn't control. Could a giant copy it? No, they are blocked.
03
What protects it. Korean regulatory approvals, manufacturing scale, and distribution ties built over 85 years keep it inside the country's top five drugmakers.
What would change this call
Gliatilin clawback appeal ruling outcome. A loss would crystallize a refund liability exceeding CKD's annual net income.
CKD-510 Phase 2 atrial fibrillation readout, H2 2027. Positive data would validate the Novartis-partnered pipeline as a genuine growth driver.
Next 2-3 quarterly revenue prints excluding Wegovy contribution. Shows whether legacy drug decline is stabilizing or accelerating.
Key numbers
  • FY2025 revenue ₩1.69T, up 6.68% YoY (2025-12-31)
  • Wegovy added ₩48.8B in Q1 2026, more than all revenue growth (2026-03-31)
  • Gliatilin clawback liability exceeds ₩100B (2026-05-31)
Named risks
  • Gliatilin clawback appeal loss could trigger over ₩100 billion refund vs ₩77.8 billion FY2025 net income. Severity: high
  • Core business ex-Wegovy shows negative growth, masked by low-margin Novo distribution deal. Severity: medium
  • Legacy drug patent cliffs eroding revenue: Prolia -33.3%, Gliatilin -29.5% in recent periods. Severity: medium
  • Excluded from Nature's July 2026 Korean biotech innovation leader rankings, unlike peers. Severity: medium
  • Siheung complex follow-up investment equals 39% of consolidated equity, execution risk through 2028. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Yuhan Corporationlosing toYuhan ₩2.19T vs CKD ₩1.69T 2025 sales, ranked #1 in Korea, 2025-12-31
GC Biopharmalosing toGC Biopharma ₩1.99T vs CKD ₩1.69T 2025 sales, ranked #2, 2025-12-31
Daewoong Pharmaceuticalgaining onCKD ₩1.69T ahead of Daewoong ₩1.57T 2025 sales
Hanmi Pharmaceuticallosing toNature named Hanmi an Innovation Leader July 2026 while CKD was excluded from rankings
Sam Chun Dang PharmcontestingRival secured 11-country Europe oral semaglutide generics deal, Feb 26 2026
Questions people ask
Is Chong Kun Dang profitable in 2026?
Yes. Chong Kun Dang posted Q1 2026 operating profit of ₩17.6 billion, up 36.9% YoY, on revenue of ₩447.7 billion, per a May 29, 2026 report. FY2025 net income was ₩77.8 billion on ₩1.69 trillion revenue, though much of the recent growth came from lower-margin Wegovy distribution rather than core drug sales.
What is Chong Kun Dang's biggest competitor in Korea?
Yuhan Corporation (₩2.19 trillion 2025 sales) and GC Biopharma (₩1.99 trillion) rank above Chong Kun Dang's ₩1.69 trillion, making it Korea's third-largest of the top five pharma firms as of December 31, 2025, per Chosun's February 19, 2026 report.
Could AI replace Chong Kun Dang's drug manufacturing jobs?
Partially for documentation, not for core operations. In January 2026 LG CNS deployed AgenticWorks AI agents to cut APQR quality-report generation time by over 90%, but regulatory approvals, clinical trial data, and NHI reimbursement relationships remain non-automatable, per a January 20, 2026 report.
Is Chong Kun Dang facing any major lawsuits?
Yes. Chong Kun Dang lost a September 2025 trial contesting a National Health Insurance clawback tied to its Gliatilin drug and is now on appeal; refund liability already exceeds ₩100 billion, and losing would require refunding 20% of prescription revenue, per a May 22, 2026 report.
Is Chong Kun Dang's revenue growth real or driven by one deal?
Much of it comes from one deal. In Q1 2026 Wegovy co-promotion contributed ₩48.8 billion, exceeding the entire ₩46.8 billion revenue increase, meaning core legacy products like Prolia (-33.3%) and Gliatilin (-29.5%) actually declined, per a May 22, 2026 report.
Who owns Chong Kun Dang?
Chong Kun Dang Pharmaceutical Corp. (KRX:185750) is publicly listed and majority controlled by holding company Chong Kun Dang Holdings Corp. (KRX:001630). Market cap was approximately ₩1.05 trillion as of May 28, 2026, per stockanalysis.com.
Timeline
  • 2026-07-02Nature-cited ranking excludes Chong Kun Dang from Korean biotech innovation leader tiers
  • 2026-06-30Board approves ₩392.5 billion follow-up investment for Siheung bio complex
  • 2026-05-29Q1 2026 earnings beat estimates, revenue up 12.2% YoY driven by Wegovy sales
  • 2026-05-22Report reveals ex-Wegovy core business declined; Gliatilin refund liability tops ₩100 billion
  • 2026-03-31Introduces in-house LLM and Metaverse Factory control system at Cheonan plant
  • 2026-02-26Rival Sam Chun Dang secures 11-country European oral semaglutide generics deal
  • 2026-02-13FY2025 results reported: revenue ₩1.69 trillion, net income ₩77.8 billion
  • 2026-01-20LG CNS deploys AgenticWorks AI platform to automate APQR quality reports
  • 2025-10-31Begins co-promoting Novo Nordisk's Wegovy in South Korea
  • 2025-09-30Loses first trial over Gliatilin NHI clawback; appeal ongoing
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources